Consolidated Statements of Cash Flows - USD ($)
|
12 Months Ended |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
| CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
| Net loss |
$ (20,184,000)
|
$ (16,643,000)
|
$ (12,373,000)
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
| Depreciation |
1,503,000
|
810,000
|
311,000
|
| Amortization |
159,000
|
28,000
|
15,000
|
| Provision for bad debts |
413,000
|
215,000
|
0
|
| Stock-based compensation |
2,834,000
|
3,835,000
|
735,000
|
| Stock-based research and development/general and administrative expenses |
0
|
0
|
427,000
|
| Change in fair value of contingent consideration liability |
(269,000)
|
(198,000)
|
0
|
| Change in fair value of warrant liability |
(35,000)
|
(417,000)
|
(4,633,000)
|
| Amortization of loan guarantee, financing fees and debt issuance costs |
8,000
|
311,000
|
1,195,000
|
| Accretion of discount on debt |
0
|
0
|
585,000
|
| Loss in equity-method investment |
707,000
|
940,000
|
12,000
|
| Loss on conversion of debt to equity |
0
|
0
|
6,850,000
|
| Deferred initial public offering costs expensed |
0
|
0
|
618,000
|
| Change in working capital components: |
|
|
|
| Accounts receivable |
(1,662,000)
|
(1,657,000)
|
(717,000)
|
| Other current assets |
(384,000)
|
(199,000)
|
(375,000)
|
| Other non-current assets |
(101,000)
|
0
|
0
|
| Accounts payable, accrued expenses and deferred revenue |
3,114,000
|
675,000
|
(731,000)
|
| Deferred rent and other |
(33,000)
|
(38,000)
|
6,000
|
| Net cash (used in) operating activities |
(13,599,000)
|
(12,338,000)
|
(8,075,000)
|
| CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
| Purchase of fixed assets |
(1,008,000)
|
(1,374,000)
|
(257,000)
|
| (Increase) decrease in restricted cash |
6,000,000
|
(6,000,000)
|
(50,000)
|
| Patent costs |
(137,000)
|
(130,000)
|
(92,000)
|
| Investment in joint venture |
0
|
(1,000,000)
|
(1,000,000)
|
| Cash used in acquisition of Gentris, net of cash received |
0
|
(3,181,000)
|
0
|
| Cash from acquisition of BioServe |
0
|
312,000
|
0
|
| Cash used in acquisition of Response Genetics |
(7,495,000)
|
0
|
0
|
| Net cash (used in) investing activities |
(2,640,000)
|
(11,373,000)
|
(1,399,000)
|
| CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
| Principal payments on capital lease obligations |
(83,000)
|
(44,000)
|
(17,000)
|
| Payment of equity issuance costs |
(117,000)
|
0
|
0
|
| Proceeds from public offerings of common stock, net of offering costs |
10,353,000
|
0
|
61,517,000
|
| Proceeds from warrant exercises |
1,000
|
178,000
|
192,000
|
| Proceeds from option exercises |
23,480
|
79,018
|
1,640
|
| Payment of debt issuance costs |
(33,000)
|
0
|
0
|
| Principal payments on notes payable |
0
|
(408,000)
|
(3,580,000)
|
| Net cash provided by (used in) financing activities |
10,144,000
|
(195,000)
|
58,114,000
|
| Net increase (decrease) in cash and cash equivalents |
(6,095,000)
|
(23,906,000)
|
48,640,000
|
| CASH AND CASH EQUIVALENTS |
|
|
|
| Beginning |
25,554,000
|
49,460,000
|
820,000
|
| Ending |
19,459,000
|
25,554,000
|
49,460,000
|
| SUPPLEMENTAL CASH FLOW DISCLOSURE |
|
|
|
| Cash paid for interest |
240,000
|
128,000
|
608,000
|
| SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES |
|
|
|
| Fixed assets acquired through capital lease arrangements |
0
|
42,000
|
354,000
|
| Warrants issued for financing fees |
0
|
0
|
47,000
|
| Retirement of treasury stock |
0
|
0
|
17,000
|
| Conversion of notes payable and lines of credit to common stock |
0
|
0
|
9,634,000
|
| Value of shares issued as partial consideration to acquire businesses |
0
|
1,516,000
|
0
|
| Reclassification of derivative warrants |
0
|
0
|
7,170,000
|
| Cashless exercise of derivative warrants |
0
|
125,000
|
420,000
|
| Offering costs discounted |
0
|
0
|
733,000
|
| Net tangible assets acquired via acquisition |
2,843,000
|
1,255,000
|
0
|
| Accrued expenses reclassified as derivative warrant liability |
0
|
0
|
221,000
|
| BioServe |
|
|
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
| Change in fair value of contingent consideration liability |
269,000
|
(198,000)
|
0
|
| Gentris Corporation |
|
|
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
| Change in fair value of contingent consideration liability |
(207,000)
|
0
|
0
|
| Response Genetics |
|
|
|
| SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES |
|
|
|
| Value of shares issued as partial consideration to acquire businesses |
$ 5,436,000
|
$ 0
|
$ 0
|